A fascinating and somewhat unsettling observation from JACC: Asia: nearly 1 in 4 STEMI patients in New Delhi had no traditional risk factors—no hypertension, diabetes, dyslipidemia, or smoking.

Yet outcomes tell a different story. Despite fewer signs of heart failure at presentation, these patients had worse left ventricular dysfunction and identical in-hospital and 1-year mortality compared with those with standard risk factors.

This "SMuRF-less paradox" challenges our conventional risk models. It reminds us that absence of risk factors is not absence of risk.

We may need to think beyond the usual suspects—toward genetics, inflammation, lipoprotein(a), and healthcare access delays—to truly understand and prevent cardiovascular disease.

A humbling lesson: treat aggressively, think broadly, and never be reassured by a "clean" risk profile.

A thoughtful and important JACC State-of-the-Art Review reframes cardiogenic shock not as a single ICU event, but as a longitudinal survivorship journey.

The article highlights recovery, remission, native heart survival, PICS, HF GDMT optimization, and the need for structured multidisciplinary postshock clinics focused on function, cognition, quality of life, and recurrent risk after discharge.

A timely call to move from rescue alone to rescue plus recovery.

A landmark 10-year follow-up of the HOST-EXAM trial published in The Lancet challenges a century-old assumption: aspirin may no longer be the default for lifelong secondary prevention after PCI.

Clopidogrel demonstrated a sustained reduction in ischemic and bleeding events (HR 0.86, p=0.005), with benefits that accumulated over time—yet without a mortality difference.

The implication is subtle but profound: we may be witnessing the quiet reshaping of antiplatelet strategy.

In cardiology, tradition often lingers—but data, eventually, prevails.

🫀 In the New England Journal of Medicine, the SMART-DECISION trial asks a practical modern question: after myocardial infarction, should stable patients without heart failure or marked left ventricular systolic dysfunction remain on beta-blockers indefinitely?

In this randomized noninferiority trial, stopping beta-blockers after at least 1 year was noninferior to continuing them for the composite of death, recurrent myocardial infarction, or hospitalization for heart failure. A provocative study that may help us prune old habits with newer evidence.

The New England Journal of Medicine has now given us randomized trial evidence for a question long guided more by extrapolation than by direct proof: in patients with established atherosclerotic cardiovascular disease, targeting LDL cholesterol to

Elegant trial, practical message: when risk is high, lower may truly be better. 🫀📉🎯 Journal: New England Journal of Medicine.

New in Circulation: the 2026 AHA Dietary Guidance to Improve Cardiovascular Health distills prevention into 9 elegant features—maintain healthy weight, emphasize vegetables/fruits, choose whole grains, favor healthier proteins and unsaturated fats, minimize ultraprocessed foods, added sugars, and sodium, and avoid starting alcohol for health. Food, here, is not garnish; it is strategy. 🥗🌾🩺 #Cardiology #Preven

📚 From prisons to clinics to classrooms — what really shapes us?

I've been exploring the philosophical work of Michel Foucault, and one idea keeps echoing:

👉 Power isn't just something imposed from above — it quietly operates through systems, language, and everyday norms.

From how we define "normal" to how institutions like schools, hospitals, and prisons function, Foucault challenges us to rethink what we take for granted.

🔍 His work invites us to ask:

• Who defines truth?

• How do labels shape identity?

• When does care become control?

Whether you're in education, healthcare, research, or leadership, these questions feel surprisingly relevant today.

🧠 Sometimes the most powerful shift is not in changing the world — but in seeing it differently.

#Philosophy #Foucault #CriticalThinking #Education #Healthcare #Leadership #IntellectualCuriosity #IdeasThatMatter

Left atrial appendage closure—promise meets proof, and proof meets pause.

In The New England Journal of Medicine, two pivotal trials draw a nuanced arc:

CHAMPION-AF shows noninferior stroke prevention with less bleeding vs direct oral anticoagulants, while CLOSURE-AF tempers enthusiasm—failing noninferiority in older, high-risk patients with meaningful procedural risk.

The message is elegant and sobering: innovation must bow to evidence, and patient selection remains paramount.

In atrial fibrillation, the art lies not in closing the appendage—but in opening judgment.

Evolocumab steps into primary prevention—quietly, convincingly. In JAMA, the VESALIUS-CV analysis shows that high-risk patients with diabetes without known atherosclerosis experienced a 31% relative reduction in first MACE (HR 0.69), with LDL-C lowered to ~52 mg/dL. The signal is clear: earlier, deeper lipid lowering matters. Yet questions remain—cost, long-term safety, and who benefits most. Are we ready to treat risk before disease declares itself? 🧠💉📉 #JAMA #Cardiology #Prevention

A quiet valve, a loud message. 🫀

The 10-year follow-up of the RECOVERY trial in The New England Journal of Medicine shows that early surgery in asymptomatic very severe aortic stenosis is not premature—it is protective.

A striking reduction in cardiovascular mortality (HR 0.10, P=0.002) and sustained divergence of Kaplan–Meier curves challenge the long-held "watchful waiting" paradigm.

Perhaps we are not treating symptoms—but preventing myocardial destiny.

#Cardiology #AorticStenosis #NEJM #PrecisionMedicine